RxDoctor Payments Data

Arash Tabaee, MD

Cardiovascular Disease · N Chelmsford, MANPI 1962499608

Payments from drug & device makers

$742in general payments, 2019–2025

Across 31 payments — averaging $23.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$309
  • Pfizer$133
  • AstraZeneca$96
  • Amgen$50
  • Lantheus Medical Imaging, Inc.$44
  • Merck$39
  • plus $71 from 4 others

What the payments were for

  • Food & beverage$742100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$742 in reported general payments places this provider in the 40th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$260,601
Medicare patients
1,896
Services billed
3,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban506$597,109
EntrestoSacubitril/Valsartan82$116,210
XareltoRivaroxaban111$114,216
JardianceEmpagliflozin23$18,217
Repatha SureclickEvolocumab13$17,221
Metoprolol Succinate658$14,590
Atorvastatin Calcium543$9,591
Rosuvastatin Calcium133$3,567
Labetalol Hcl71$3,171
Ezetimibe55$2,795
Diltiazem 24hr Er (Cd)Diltiazem Hcl64$2,770
ClopidogrelClopidogrel Bisulfate131$2,628
Torsemide111$2,415
Amlodipine Besylate304$2,052
Eplerenone24$1,884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$133$597,109506 claims
NovartisEntresto$309$116,21082 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in N Chelmsford

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →